Antidepressant Suicide Risk May Be Double For Children: Study

Danish researchers warn that the side effects of certain antidepressants may increase the risk of suicide when used by children. 

In a study published in the medical journal The BMJ on on January 27, researchers from the University of Copenhagen and the Nordic Cochrane Centre in Denmark found that the use of antidepressants such as Zoloft, Paxil, Cymbalta, Effexor and Prozac doubled the risk of suicide and aggressive behavior in children.

All of the drugs, except Effexor, belong to a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). Effexor is part of a closely related class known as serotonin and norepinephrine reuptake inhibitors.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Researchers looked at data on 70 different drug trials involving 18,526 patients. They found that while there were slight increases in the risk of death, and suicidality, aggression and akathisia (a movement disorder caused by restlessness) among adults, the increases were statistically insignificant.

In children using antidepressants, the findings were more pronounced. Children who used drugs like Zoloft, Paxil and Effexor were found to have more than twice the risk of death, suicide, restlessness and aggression, the researchers found.

“In adults there were no significant increases in all four outcomes, but in children and adolescents the risk of suicidality and aggression doubled,” the researchers warned. “To elucidate the harms reliably, access to anonymised individual patient data is needed.”

Researchers also warned that there were problems with trial reports and adverse events posted to Eli Lilly’s website regarding its Cymbalta and Prozac antidepressants, raising concerns about the information being provided to doctors and potential users.

“Information was limited on adverse events in these summary reports and it was not reliable,” the researchers noted. “The number of serious events was always mentioned but the cases were not always explained and the reports focused on the most common adverse events.”

In 2004, the FDA placed a “black box warning” on Prozac and other SSRI antidepressants, indicating that the drugs have been linked to an increased risk of suicide for children and young adults under the age of 25. The warning was based on the findings of 25 previous clinical trials that led to the conclusion.

SSRIs are a relatively new class of antidepressants, which help reduce symptoms of depression by preventing certain nerve cells in the brain from re-absorbing the chemical serotonin. These drugs are commonly used by millions of Americans with depression.

Although the drugs have been found to cause fewer side effects than older anti-depressants, previous studies have shown that users of the drugs could face an increased risk of suicides, and use during pregnancy has been linked to a risk of birth defects from SSRI antidepressants.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Port Catheter Infection Lawsuits Over Bard PowerPort Devices Claim Faulty Design Promotes Colonization of Bacteria
Port Catheter Infection Lawsuits Over Bard PowerPort Devices Claim Faulty Design Promotes Colonization of Bacteria (Posted today)

Hundreds of currently pending Bard PowerPort lawsuits over infections, fractures and migration injuries were consolidated into a multidistrict litigation (MDL), but now even more claims present similar allegations that the implantable port catheter system has dangerous design defects that were not adequately disclosed by the manufacturer.

Johnson & Johnson Increases Talcum Powder Settlement Offer by $1.1B: Reuters
Johnson & Johnson Increases Talcum Powder Settlement Offer by $1.1B: Reuters (Posted today)

A recent report suggests that Johnson & Johnson is offering an additional $1.1 billion to settle talcum powder lawsuits, as part of a proposed $9 billion deal that would resolve all ovarian cancer claims as part of a third bankruptcy filing by the manufacturer.

Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits
Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits (Posted 3 days ago)

A federal judge has agreed to divide lawsuits over gastroparesis injuries linked to drugs like Ozempic and Mounjaro into multiple phases, examining how the condition is diagnosed and whether plaintiffs' claims are preempted by federal laws.